Advertisement
U.S. markets close in 2 hours 20 minutes
  • S&P 500

    5,251.37
    +2.88 (+0.05%)
     
  • Dow 30

    39,763.89
    +3.81 (+0.01%)
     
  • Nasdaq

    16,380.38
    -19.14 (-0.12%)
     
  • Russell 2000

    2,124.33
    +9.98 (+0.47%)
     
  • Crude Oil

    82.77
    +1.42 (+1.75%)
     
  • Gold

    2,239.30
    +26.60 (+1.20%)
     
  • Silver

    24.92
    +0.17 (+0.70%)
     
  • EUR/USD

    1.0799
    -0.0030 (-0.28%)
     
  • 10-Yr Bond

    4.2040
    +0.0080 (+0.19%)
     
  • GBP/USD

    1.2625
    -0.0013 (-0.10%)
     
  • USD/JPY

    151.3540
    +0.1080 (+0.07%)
     
  • Bitcoin USD

    70,726.13
    +1,641.95 (+2.38%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Dynavax to Present at the 31st Annual J.P. Morgan Healthcare Conference

BERKELEY, CA--(Marketwire - Dec 17, 2012) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 7, 2013 at 6:00 p.m. Eastern Time (3:00 p.m. Pacific Time).

Dino Dina, M.D., Chief Executive Officer of Dynavax, will provide a company overview. To access the slide presentation, live webcast, and subsequent archived recording, please visit Dynavax's website at http://investors.dynavax.com/newsevents.cfm.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Dynavax's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.

Advertisement